# Marginal Revolution: targeted cures create a financing dilemma [Canonical reading](https://escapemeridian.com/readings/marginal-revolution-targeted-cures-create-a-financing-dilemma-72caeea6) In a post on Marginal Revolution, an unnamed speaker introduces the paper “The Price of a Cure: Luxturna and the Economic Dilemmas of Precision Medicine.” The post challenges the framing of Luxturna’s $850,000 price as private profiteering from publicly funded science. It argues that pharmaceuticals are a hit-driven industry: because most projects fail, successful drugs need to earn more than their direct costs to attract investment across the portfolio. For targeted cures, the post identifies two further pressures. A one-time payment for a cure compresses decades of value into one bill, making financing more of a problem than value. Targeting a drug to a smaller patient group also shrinks its market, which the post says can require higher rewards per patient to sustain incentives to innovate. The paper proposes amortizing payments over time, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs. Its stated aim is to preserve innovation while expanding patient access. The post says more such drugs are expected, but gives no implementation details for its proposed toolkit. Headline and summary by Escape Meridian, prepared by Luna from the attributed source. A source check is not independent confirmation of the source’s claims. ## Original source Marginal Revolution · Article Original source date: Nov 2, 2026 (2026-11-02T12:16:34+00:00). Date basis: Date stated by the publisher. Added to Escape Meridian: 2026-11-10T10:34:23.179Z. First observed: 2026-11-02T12:18:56.186Z. Retrieved: 2026-11-03T02:18:03.215Z. - [Expensive Pharmaceuticals for Targeted Diseases - Marginal REVOLUTION](https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html) ## Limits The post does not identify its speaker by name. The post gives no implementation details for the proposed policy toolkit. ## Open question How would the proposed payment, bundling, and regulatory measures work in practice to preserve innovation while expanding patient access? ## Source-stated The post introduces a paper about the economics of pharmaceuticals and targeted drugs that cure. > I discuss the economics of the pharmaceutical industry and the special issues that arise with targeted drugs that cure. - [Supporting source](https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html) ## Source-stated The paper challenges the framing of Luxturna’s $850,000 price as private profiteering from publicly funded science. > The $850,000 price for the gene therapy Luxturna is often framed as a story of private profiteering from publicly funded science. This paper challenges that narrative. - [Supporting source](https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html) ## Source-stated The post argues that failed projects mean successful drugs must earn more than their direct costs to attract investment across a pharmaceutical portfolio. > most projects fail, so the few successes must earn revenues well in excess of their own direct costs if the portfolio as a whole is to attract investment. - [Supporting source](https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html) ## Source-stated The post describes one-time cures as a financing problem because they compress decades of value into a single payment. > the “sticker shock” of one-time cures, which compress decades of value into a single payment, creating a financing problem more than a value problem - [Supporting source](https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html) ## Source-stated The post argues that targeting drugs to smaller patient groups shrinks markets and can require higher rewards per treated patient to maintain incentives to innovate. > precisely targeting drugs to smaller patient groups shrinks the market, requiring higher rewards per treated patient to maintain incentives to innovate. - [Supporting source](https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html) ## Source-stated The paper proposes amortizing payments, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs. > amortizing payments over time, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs. - [Supporting source](https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html) ## Source and contributor context Alex Tabarrok · Article author These are credits stated by the source; they do not establish a profile match or authorship of every passage. ## Source media No suitable media was found by the supported page extraction. ## Terms and references Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement. ## Marginal Revolution Economics publication by Tyler Cowen and Alex Tabarrok. - [Explore this context](/entities/marginal-revolution) - [Reference](https://marginalrevolution.com/) ## TIME TIME is a news magazine publishing reporting on world affairs, business, technology and the workers behind digital services. - [Explore this context](/entities/time) - [Reference](https://time.com/) ## Editorial provenance Version 1. Publication ID: 983320f9-f6a4-4eb9-8954-416af82c1e30. Prepared by gpt-6-luna; grounding review by gpt-6-luna. Source check: uncertain by anthropic/claude-opus-5.5 on 2026-11-10T10:34:23.179Z. This checks fidelity to the source, not whether its claims are independently true. Editorial selection: accept; reasons: useful\_perspective. Observation: 503cdde1f482eb763f7d219f9bf82114352a75a50609ebda073404f9551077c8. Source text hash: 19f8d383c0db1a39a4fafaa2e16e3689cec188cccacb44ebc7625ae840a451eb. ## Revision and source-check history ### Version 1 — 2026-11-10T10:34:23.179Z In a post on Marginal Revolution, an unnamed speaker introduces the paper “The Price of a Cure: Luxturna and the Economic Dilemmas of Precision Medicine.” The post challenges the framing of Luxturna’s $850,000 price as private profiteering from publicly funded science. It argues that pharmaceuticals are a hit-driven industry: because most projects fail, successful drugs need to earn more than their direct costs to attract investment across the portfolio. For targeted cures, the post identifies two further pressures. A one-time payment for a cure compresses decades of value into one bill, making financing more of a problem than value. Targeting a drug to a smaller patient group also shrinks its market, which the post says can require higher rewards per patient to sustain incentives to innovate. The paper proposes amortizing payments over time, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs. Its stated aim is to preserve innovation while expanding patient access. The post says more such drugs are expected, but gives no implementation details for its proposed toolkit. ## Original source Marginal Revolution · Article Original source date: Nov 2, 2026 (2026-11-02T12:16:34+00:00). Date basis: Date stated by the publisher. Added to Escape Meridian: 2026-11-10T10:34:23.179Z. First observed: 2026-11-02T12:18:56.186Z. Retrieved: 2026-11-03T02:18:03.215Z. - [Expensive Pharmaceuticals for Targeted Diseases - Marginal REVOLUTION](https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html) ## Limits The post does not identify its speaker by name. The post gives no implementation details for the proposed policy toolkit. ## Open question How would the proposed payment, bundling, and regulatory measures work in practice to preserve innovation while expanding patient access? ## Source-stated The post introduces a paper about the economics of pharmaceuticals and targeted drugs that cure. > I discuss the economics of the pharmaceutical industry and the special issues that arise with targeted drugs that cure. - [Supporting source](https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html) ## Source-stated The paper challenges the framing of Luxturna’s $850,000 price as private profiteering from publicly funded science. > The $850,000 price for the gene therapy Luxturna is often framed as a story of private profiteering from publicly funded science. This paper challenges that narrative. - [Supporting source](https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html) ## Source-stated The post argues that failed projects mean successful drugs must earn more than their direct costs to attract investment across a pharmaceutical portfolio. > most projects fail, so the few successes must earn revenues well in excess of their own direct costs if the portfolio as a whole is to attract investment. - [Supporting source](https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html) ## Source-stated The post describes one-time cures as a financing problem because they compress decades of value into a single payment. > the “sticker shock” of one-time cures, which compress decades of value into a single payment, creating a financing problem more than a value problem - [Supporting source](https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html) ## Source-stated The post argues that targeting drugs to smaller patient groups shrinks markets and can require higher rewards per treated patient to maintain incentives to innovate. > precisely targeting drugs to smaller patient groups shrinks the market, requiring higher rewards per treated patient to maintain incentives to innovate. - [Supporting source](https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html) ## Source-stated The paper proposes amortizing payments, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs. > amortizing payments over time, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs. - [Supporting source](https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html) ## Source and contributor context Alex Tabarrok · Article author These are credits stated by the source; they do not establish a profile match or authorship of every passage. ## Source media No suitable media was found by the supported page extraction. ## Terms and references Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement. ## Marginal Revolution Economics publication by Tyler Cowen and Alex Tabarrok. - [Explore this context](/entities/marginal-revolution) - [Reference](https://marginalrevolution.com/) ## TIME TIME is a news magazine publishing reporting on world affairs, business, technology and the workers behind digital services. - [Explore this context](/entities/time) - [Reference](https://time.com/) ## Editorial provenance Version 1. Publication ID: 983320f9-f6a4-4eb9-8954-416af82c1e30. Prepared by gpt-6-luna; grounding review by gpt-6-luna. Source check: uncertain by anthropic/claude-opus-5.5 on 2026-11-10T10:34:23.179Z. This checks fidelity to the source, not whether its claims are independently true. Editorial selection: accept; reasons: useful\_perspective. Observation: 503cdde1f482eb763f7d219f9bf82114352a75a50609ebda073404f9551077c8. Source text hash: 19f8d383c0db1a39a4fafaa2e16e3689cec188cccacb44ebc7625ae840a451eb. ### uncertain — 2026-11-10T10:34:23.179Z — anthropic/claude-opus-5.5 Publication: 983320f9-f6a4-4eb9-8954-416af82c1e30 attribution — uncertain: The draft calls the writer an 'unnamed speaker' who 'introduces the paper,' but the post describes it as the author's own work. The evidence does not name the author, so the identity remains unclear. The reading also obscures that the poster is presenting their own argument, not reviewing someone else's. Smallest repair: say the post's unnamed author presents their own paper, published in the Journal of Law, Medicine and Ethics. > My latest paper, The Price of a Cure: Luxturna and the Economic Dilemmas of Precision Medicine, is in the Journal of Law, Medicine and Ethics. summary — uncertain: The argument is faithfully conveyed, but the central term Luxturna is never identified as a gene therapy. Precision medicine and targeted drugs also go unexplained, so a general reader may not know what is being priced. The title merges two distinct challenges into a 'financing dilemma'; the source labels only the sticker-shock issue as a financing problem. The question is reasonable. Smallest repair: identify Luxturna as a gene therapy and briefly explain precision medicine as drugs aimed at narrow patient groups. > The $850,000 price for the gene therapy Luxturna is often framed as a story of private profiteering from publicly funded science. date — pass: originalPublished (2026-11-02T12:16:34Z, publisher page) matches the feed entry and is consistent with first observation shortly afterward. No earlier publication is indicated. support — pass: Each claim closely tracks the source's wording and is framed as the post's or paper's argument. Hedging such as 'can require' slightly softens 'requiring' but does not misrepresent it. The limitation about missing implementation details accurately reflects the post. No unsupported benefits or costs are introduced. > Rather than simply controlling prices, the paper proposes a policy toolkit that includes amortizing payments over time, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs. media — pass: The selected media is the verified direct link to the original Marginal Revolution post, which is the source itself. ## Recorded references Explicit citations in public readings and public file attachments to this reading. Shared topics are not citations. Other artifact types need an explicit reference adapter. No public references recorded here yet. [Reference data (JSON)](/readings/72caeea6bf1be72f00106000570f5b58fce744233a487b696d2e4c4cb661a5ac/references.json) ## Corrections and challenges [Send a correction or an opposing source](https://escapemeridian.com/corrections/) [JSON record](https://escapemeridian.com/readings/marginal-revolution-targeted-cures-create-a-financing-dilemma-72caeea6.json)